GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » YoY Rev. per Sh. Growth

Mesoblast (Mesoblast) YoY Rev. per Sh. Growth : -100.00% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Mesoblast's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 was -100.00%.

Mesoblast's Revenue per Share for the three months ended in Dec. 2023 was $0.00.

Mesoblast YoY Rev. per Sh. Growth Historical Data

The historical data trend for Mesoblast's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast YoY Rev. per Sh. Growth Chart

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.57 78.13 -78.95 25.00 -33.33

Mesoblast Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.33 - -100.00 -100.00 -100.00

Mesoblast YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Mesoblast's YoY Rev. per Sh. Growth for the fiscal year that ended in Jun. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Jun. 2023 )
=(Revenue per Share (A: Jun. 2023 )-Revenue per Share (A: Jun. 2022 ))/ | Revenue per Share (A: Jun. 2022 ) |
=(0.01-0.015)/ | 0.015 |
=-33.33 %

Mesoblast's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2023 )
=(Revenue per Share (Q: Dec. 2023 )-Revenue per Share (Q: Dec. 2022 )) / | Revenue per Share (Q: Dec. 2022 )) |
=(0-0.003)/ | 0.003 |
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Mesoblast's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast (Mesoblast) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
ASX:CU6 ASX:CUV ASX:IMU ASX:IMM ASX:OPT ASX:PYC ASX:BOT ASX:RAC ASX:DXB ASX:PIQ OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
MESO:USA LWB:Germany MSB:Australia
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Website
https://www.mesoblast.com
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.